Featured

All content

Media
Our response to COVID-19 and how we built on our experience and knowledge of remote patient monitoring to make a difference.
2020-05-19
Media
Our story – how together with Microsoft and Cognizant we tried to make a difference during COVID-19
2020-05-19
Blog
The COVID-19 pandemic has swept across the world in recent months. At the time of writing, in the UK, the pandemic has been responsible for over 34,000 confirmed deaths. The UK National Health Service has been tested like never before in its 70 years of existence, with intensive care units across the country experiencing an unparalleled surge in patients requiring critical care.
2020-05-18
Blog
Determining Risk factors for clinical progression in patients with COVID-19
2020-05-18
Press release
Sensyne Health plc (LSE: SENS), the UK Clinical AI technology company, today announces a trading update (unaudited) for the year ended 30 April 2020. The Company will report its audited full year 2020 results in September 2020.
2020-05-14
Press release
Trading and Business Update
2020-05-14
Blog
Like many in the bioscience industry, Sensyne is seeking ways to turn its resources and expertise into valuable contributions towards research into COVID-19. In our case, one way we did this was to commit this expertise, in the form of our multidisciplinary Discovery Sciences team comprising clinicians, epidemiologists, biologists, machine learning researchers and data scientists, to a Coronavirus-focussed weekend virtual hackathon.
2020-05-06
Blog
A weekend, a ‘virtual’ hackathon and ML approaches to automate the analysis of COVID-19 lung CT scans
2020-05-06
Press release
Oxford, U.K. 05 May 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI technology company, today announces it has launched BPm-Health to help pregnant women monitor blood pressure remotely in response to the UK government guidelines for all pregnant women to follow stringent social distancing and minimise face-to-face contact.
2020-05-05
Press release
Sensyne Health announces launch of new BPm-Health™ remote monitoring system for the management of blood pressure in pregnancy in response to COVID-19 pandemic
2020-05-05
Blog
Today we announced the launch of CVm-Health the ‘Good Neighbour app’, a software application to help people monitor their health during the pandemic, not just for those with COVID-19, but for everyone – sick or well, young or old, to help the public and the NHS understand and mitigate the effects of this virus.
2020-04-20
Blog
Connecting in a time of disconnection
2020-04-20
Case study
Diabetes during pregnancy can affect women due to pre-existing Type 1 or Type 2 diabetes, or a condition known as gestational diabetes when glucose intolerance is confined to the pregnancy and resolves afterwards. Gestational Diabetes is increasing in prevalence worldwide, driven by demographic and lifestyle changes. In the UK, the rise is predicted to reach over 16% this year, from a baseline of around 4% in 2008 [1].
2020-03-19
Case study
GDm-Health – an award-winning digital health solution for diabetes during pregnancy
2020-03-19
Press release
Sensyne Health awarded a prestigious HSJ Partnership Award in providing a digital health solution for diabetes during pregnancy that has helped prevent pre-term births, C-sections and the need for pharmacological treatment. Diabetes during pregnancy affects thousands of mothers-to-be each year and can lead to serious complications in pregnancy.
2020-02-28
Press release
Sensyne Health recognised for its impact in helping treat diabetes in pregnancy
2020-02-28
Case study
Heart failure affects over one million adults in the UK, is increasing, is one of the commonest causes of admission to hospital and is responsible for 10,000 deaths a year. Overall the 5-yr survival rate is worse than cancer: about 50% compared with cancer at 85%. Heart failure severely compromises patient’s quality of life, and has a significant economic impact representing 1-2% of the NHS annual budget (c. £625 million).
2020-01-21
Case study
Study on benefits of blood anticoagulants for heart failure patients
2020-01-21
Case study
The US currently spends approximately 18%of its GDP on healthcare, compared to 10%in the UK. There are significant potential opportunities to introduce healthcare innovations that have been developed and validated by Sensyne Health, working in partnership with the NHS, to be exported to the US. In January 2019 Sensyne Health entered into a collaboration with Jefferson Health’s Strategic Ventures arm to undertake a clinical and health-economic evaluation of Sensyne Health’s digital health products to determine their potential in the US market.
2020-01-15
Case study
Evaluating the potential for Sensyne in the US healthcare market – our collaboration with Jefferson Health
2020-01-15
Media
Dr Rabia Khan commenting on the future of personalised medicine at CSCHealth19
2020-01-14
Media
What is the future of personalised medicine?
2020-01-14
Press release
NHS staff are uncomfortable with multinational ‘big tech’ companies analysing anonymised patient data, according to a new survey.
2019-11-23
Press release
NHS staff fears over multinational 'big tech' firms analysing patient data
2019-11-23
Press release
London, UK: Sensyne Health is pleased to announce that it has been recognised as the winner of the Healthtech Company of the Year award at the 2019 Lifestars Awards™.
2019-11-20
Press release
Sensyne Health wins Healthtech Company of the Year award at 2019 European Lifestars Awards™
2019-11-20
Press release
Oxford, UK: Sensyne Health plc (LSE: SENS), (“Sensyne Health” or “the Company”), the British clinical AI technology company, today announces the name of its partners for the launch and sale of its digital health software products in the United States of America.
2019-11-15
Press release
Sensyne Health names Cognizant and Agorai as partners for the launch and sale of its digital health software products in the U.S.
2019-11-15
Press release
Expands on existing collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using clinical AI. Sensyne Health will partner with Bayer on inaugural LifeHub project – developing AI enabled radiology to enhance patient outcomes.
2019-10-10
Press release
Sensyne Health Partners with Bayer on New UK Artificial Intelligence ‘LifeHub’
2019-10-10
Blog
Britain is about to have a new government. And in a few months’ time, there could be a General Election resulting in the third government of 2019. On top of this, Brexit has still not been resolved.
2019-07-23
Blog
Data is our NHS’ most precious asset – the next Prime Minister must protect it
2019-07-23
Blog
With growing interest in the potential for Artificial Intelligence to find solutions to complex health challenges and relieve pressure on the NHS.
2019-06-08
Blog
Survey shows strong support for analysis of anonymised NHS patient data for medical research.
2019-06-08
Press release
New agreement provides access to anonymised patient datasets covering 1.36 million hospital admissions, for analysis using clinical artificial intelligence technology
2019-01-28
Press release
Sensyne Health and Wye Valley NHS Trust sign SRA
2019-01-28
Press release
New agreement provides access to anonymised patient datasets covering 746,000 hospital admissions, for analysis using clinical artificial intelligence technology
2019-01-28
Press release
Sensyne Health and George Eliot Hospital NHS Trust sign SRA
2019-01-28
Press release
Unique three-year alliance established between industry and academia to advance the analysis and interpretation of unique NHS datasets in chronic kidney disease and cardiovascular disease using clinical artificial intelligence (AI) to improve care and accelerate the discovery and development of new medicines
2019-01-28
Press release
New research alliance with Big Data Institute
2019-01-28
Press release
Oxford, UK; 28th January 2019: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the British Clinical AI technology company, today announces its Interim Results for the six months ended 31st October 2018.
2019-01-28
Press release
Sensyne Health Maiden Interim Results 2018
2019-01-28
Blog
Jet engines are monitored far more intensively than people to help keep passengers safe in the air. Similarly, if we are to realise the full potential of digital healthcare, individualised monitoring and robust AI techniques will be key.
2018-12-05
Blog
Monitoring Jet Engines and the Health of People
2018-12-05
Press release
Sensyne is working with a set of experts with the requisite capabilities in computing, data analytics and systems integration to deliver such a strategy.
2018-12-05
Press release
Sensyne Health welcomes UK government announcement
2018-12-05
Blog
A recent report from a working party of the Academy of Medical Sciences of which I was a member, outlines a set of principles based on dialogues with patients, the public and healthcare professionals, for the development, evaluation and deployment of data-driven technologies in healthcare.
2018-12-05
Blog
Realising the benefits of new healthcare technologies
2018-12-05
Press release
EY to support Sensyne’s mission to increase capacity to curate and analyse large numbers of anonymised datasets as it develops a global approach to the valuation of patient medical data
2018-11-21
Press release
Sensyne Health signs Strategic Advisory Services agreement with EY
2018-11-21
Press release
Regulated, cloud-based digital therapeutic product for the management of gestational diabetes, is commercially available for use across the NHS. Five NHS Trusts have signed contracts to use GDm-Health.
2018-10-16
Press release
Official product launch of GDm-Health™
2018-10-16
Media
GDm-Health™ is a direct patient-to-clinician blood glucose monitoring management system specifically designed for the management of gestational diabetes.
2018-10-16
Media
GDm-Health™ Launch Video
2018-10-16
Press release
Oxford, UK; 3rd October 2018: Sensyne Health plc (LSE: SENS),the British clinical AI technology company, today announces the appointment of Professor Lionel Tarassenko CBE FREng FMedSci as Director of Research & Development and Non-Executive Director of the Board, with immediate effect. This is in addition to his current role as Chairman of Sensyne Health’s Scientific Advisory Board.
2018-10-03
Press release
Board Appointment: Professor Lionel Tarassenko
2018-10-03
Press release
Sensyne Health plc announces it has signed a three year strategic agreement with Privitar to license its de-identification and privacy protection software.
2018-09-24
Press release
Sensyne Health licenses Privitar’s data privacy software
2018-09-24
Media
Overview of Clinical AI. Professor Lionel Tarassenko, Chairman of Sensyne Health's Scientific Advisory Board
2018-09-18
Media
Overview of Clinical AI
2018-09-18
Media
Amy Glees, Product Manager for Sensyne Health explains the need for GDm-Health™
2018-08-07
Media
The need for GDm-Health™
2018-08-07
Press release
World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.
2018-04-03
Press release
Professor David Clifton joins Drayson Health as Research Director
2018-04-03
Press release
In what is a global healthcare first, a major NHS Foundation Trust will pilot wireless environmental sensors in their intensive care units.
2017-09-29
Press release
Chelsea and Westminster Hospital partner with Drayson Health
2017-09-29